One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

• ClinicalTrials.gov Identifier: NCT01844232
• Recruitment Status: Completed
• First Posted: May 1, 2013
• Last Update Posted: April 25, 2022
• Sponsor: RVL Pharmaceuticals, Inc.
• Collaborator: Osmotica Pharmaceutical US LLC
• Information provided by (Responsible Party): RVL Pharmaceuticals, Inc.

Tracking Information

• First Submitted Date: April 24, 2013
• First Posted Date: May 1, 2013
• Last Update Posted Date: April 25, 2022
• Study Start Date: April 2013
• Actual Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 26, 2013)

Assessment of Adverse Events [ Time Frame: From the beginning of dose titration to end of study (day 393 of dosing) ]

Determination of incidence and severity of Adverse Events (AEs), discontinuations due to AEs and discontinuations due to failure of AERT to alleviate spasticity

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: April 26, 2013)

Determination of Change in Spasticity by Total Number-transformed Modified Ashworth Scale (TNmAS) [ Time Frame: From baseline (Day1, Visit 2) to end of treatment (Day 393) ]

Change in the total Numeric-transformed Modified Ashworth Scale from baseline to the end of the study (Day 393)

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
• Official Title: A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity
• Brief Summary: Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS) subjects with spasticity. All subjects in this study will receive arbaclofen in the extended release tablet formulation.

Detailed Description

Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets (AERT) over 1 year in MS subjects with spasticity. All subjects in this study will receive arbaclofen in the extended release tablet formulation.

All subjects will begin treatment with arbaclofen at 20 milligrams (mg) per day (2 X 10 mg) for two weeks, then increase to 30 mg per day (2 X 15 mg) for two weeks, and then increase to 40 mg per day (2 X 20 mg) based on the Dose Escalation Criteria. Once the subject reaches the Maintenance Dose, they will remain on that dose for approximately 1 year. The Maintenance Dose is the highest tolerated dose, not to exceed 40 mg per day.

In this study, the Up Titration Period begins with Visit 2 and ends when the Maintenance Dose is determined. The Maintenance Period is the time from establishment of the Maintenance Dose until the down-titration visit. For subjects that complete the study, the Maintenance Period is for approximately 1 year in duration. The Down Titration Period will be 2 weeks for subjects on the maintenance dose of 40 mg per day and 1 week for subjects on the maintenance dose of 30 mg per day. There is no down titration phase for subjects on a 20 mg per day maintenance dose.

Subjects for whom the Maintenance Dose is 20 mg per day (i.e., subjects who did not tolerate the 30 mg/ day dose) will begin the 1 year Maintenance Period at Visit 4 and complete the study at Visit 8. Subjects for whom the Maintenance Dose is either 30 mg or 40 mg per day will begin the Maintenance Period at Visit 5 and complete the maintenance portion of the study at Visit 9.

The next portion of the study is down titration. The subjects on the 20 mg per day Maintenance Dose will not have a down-titration. For subjects on the 30 mg per day Maintenance Dose, down-titration will begin at Visit 9 and continue for 1 week. These subjects will return for Visit 10 after the 1 week down-titration. For subjects on the 40 mg per day Maintenance Dose, down titration will begin at Visit 9 and continue for 2 weeks. These subjects will return for Visit 10 after the 2 week down-titration.

Study visits will occur every two weeks until the Maintenance Dose is reached and then study visits will occur every three months with telephone follow-up calls monthly in between visits

• Study Type: Interventional
• Study Phase: Phase 3

Study Design

Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:

All subjects will begin treatment with arbaclofen at 20 milligrams (mg) per day (2 X 10 mg) for two weeks, then increase to 30 mg per day (2 X 15 mg) for two weeks, and then increase to 40 mg per day (2 X 20 mg) based on the Dose Escalation Criteria. Once the subject reaches the Maintenance Dose, they will remain on that dose for approximately 1 year. The Maintenance Dose is the highest tolerated dose, not to exceed 40 mg per day.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• Multiple Sclerosis
• Spasticity

Intervention

Drug: arbaclofen

Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg

Other Name: OS440

Study Arms

Experimental: Arbaclofen Extended Release (ER) Tablets

Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day

Intervention: Drug: arbaclofen

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 26, 2013): 150
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: January 2015
• Actual Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Patients (male or female) 18 to 70 years of age, inclusive, at the time of the first dose.
• Have an established diagnosis (per McDonald 2005 Criteria, of Multiple Sclerosis Appendix C (either relapsing remitting or secondary progressive course), that manifests spasticity.
• If receiving disease-modifying medications (immunomodulatory treatment), these must have been at a stable dose for at least one (1) months prior to screening, and the subject must be willing to maintain this treatment for the duration of the study.
• If receiving botulinum toxin must be on a stable treatment regimen (e.g. every 12 weeks).
• If receiving phenol or alcohol injections, should have been received 60 days before enrolment in the study.
• Absence of infections and peripheral vascular disease.
• Have a creatinine clearance, as calculated by Glomerular Filtration Rate using the Modification of Diet in Renal Disease (MDRD) formula , greater than 60 milliliters/minute.
• Use of a medically highly effective form of birth control during the study and for 90 days thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects. .
• Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria:

• Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity.
• Inability to rate their level of spasticity or distinguish it from other MS symptoms.
• History of allergy to baclofen.
• Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables (Appendix D Prohibited Concomitant Medications)
• Pregnancy, lactation or planned pregnancy during the course of the study and for three months thereafter. (Confirmation that the subject is not pregnant must be established by a negative serum pregnancy test at baseline).
• History of, or current unstable psychiatric disease, or signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled renal, hepatic, gastrointestinal, hematological, endocrine, immunologic, pulmonary, cardiac or neurological disease which, in the opinion of the investigator, may; put the subject at risk because of participation, influence the result of the study, or affect the subject's ability to participate.
• Seizures requiring medication.
• Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression.
• Subjects with abnormal micturition that requires indwelling or intermittent catheterization or with lower urinary tract symptoms (LUTS) that result in a score greater than twenty-six (>26) in the Baseline Urinary Symptom Profile© questionnaire.
• Current malignancy or history of malignancy that has not been in remission for more than five years, except effectively treated basal cell skin carcinoma.
• History of substance abuse within the past twelve (12) months.
• Participation in another interventional research study within thirty (30) days of Screening except OS440-3002.
• Patients who are uncooperative or unwilling to sign consent form.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 70 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Russian Federation, Ukraine, United States

Administrative Information

• NCT Number: NCT01844232
• Other Study ID Numbers: Arbaclofen OS440-3003
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: RVL Pharmaceuticals, Inc.
• Original Responsible Party: Osmotica Pharmaceutical US LLC
• Current Study Sponsor: RVL Pharmaceuticals, Inc.
• Original Study Sponsor: Osmotica Pharmaceutical US LLC
• Collaborators: Osmotica Pharmaceutical US LLC

Investigators

• Study Chair: Praveen Tyle, Ph.D.; Osmotica Pharmaceutical

• PRS Account: RVL Pharmaceuticals, Inc.
• Verification Date: May 2015